Research Topics
| B M WolpinSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Plasma 25-hydroxyvitamin D and risk of pancreatic cancerBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
Cancer Epidemiol Biomarkers Prev 21:82-91. 2012..Laboratory studies suggest that vitamin D may inhibit pancreatic cancer cell growth. However, epidemiologic studies of vitamin D and pancreatic cancer risk have been conflicting...- Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortiumBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Cancer Epidemiol Biomarkers Prev 19:3140-9. 2010..We hypothesized: 1) A(1) allele would confer greater risk than A(2) allele, 2) protective effect of the O allele would be equivalent for O01 and O02 variants, 3) secretor phenotype would modify the association with risk... - Prospective study of ABO blood type and the risk of pulmonary embolism in two large cohort studiesBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Thromb Haemost 104:962-71. 2010..04). In two large, prospective cohorts, ABO blood type was significantly associated with the risk of idiopathic and non-idiopathic PE, with even greater risk for idiopathic PE among current and past smokers with non-O blood type... - Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortiumBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Cancer Res 70:1015-23. 2010..68 (95% CI, 2.03-3.54) compared with nonsmokers of blood type O. We concluded that ABO genotypes were significantly associated with pancreatic cancer risk... - ABO blood group and the risk of pancreatic cancerBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Natl Cancer Inst 101:424-31. 2009..ABO blood type is an inherited characteristic that in previous small studies has been associated with the risk of gastrointestinal malignancies... - Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancerBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 27:176-85. 2009..Excess energy balance leads to increased circulating insulin and depressed levels of circulating insulin-like growth factor binding protein (IGFBP) -1, which promote cancer cell growth in preclinical models... - Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 27:193-8. 2009..We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line therapy with gemcitabine... 
Prediagnostic plasma folate and the risk of death in patients with colorectal cancerBrian M Wolpin
Department of MedicalOncology, Dana Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 26:3222-8. 2008..Therefore, high priority has been given to research investigating the influence of folate on cancer progression in patients with colorectal cancer...- Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohortsB M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Br J Cancer 97:98-104. 2007..In four prospective cohorts, we found no association between the risk of pancreatic cancer and prediagnostic plasma levels of IGF-I, IGF-II, or IGFBP-3... 
Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancerBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, MA 02115, USA
Cancer Res 67:7923-8. 2007..30; 95% CI, 1.48-7.35). Among participants in four U.S. prospective cohort studies, low plasma IGFBP-1 levels significantly predicted an increased risk of pancreatic cancer...- Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studiesY Bao
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
Br J Cancer 102:1422-7. 2010..Studies evaluating vitamin D status in relation to pancreatic cancer risk have yielded inconsistent results... - A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinomaJ A Chan
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Ann Oncol 22:1367-73. 2011..We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against EGFR, in patients with unresectable or metastatic esophageal or gastric adenocarcinoma... - ABO blood group and risk of colorectal cancerHamed Khalili
Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA
Cancer Epidemiol Biomarkers Prev 20:1017-20. 2011..Recent studies have shown an association between non-O blood group and risk of pancreatic cancer. It is unclear whether this association is observed with other gastrointestinal malignancies, including colorectal cancers... - Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741Charles S Fuchs
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Clin Cancer Res 14:8263-9. 2008..We examined the influence of baseline plasma levels of IGF-I, IGF-II, IGFBP-3, and C-peptide on outcome among patients receiving first-line chemotherapy for metastatic colorectal cancer... - Prospective study of predictors of vitamin D status and survival in patients with colorectal cancerK Ng
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Br J Cancer 101:916-23. 2009.... - A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosisShuji Ogino
Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, 44 Binney St, Room JF 215C, Boston, Massachusetts 02115, USA
Am J Gastroenterol 104:2047-56. 2009..STMN1 activity is influenced by p53, p27, and the PI3K/AKT pathway. However, its prognostic significance in colon cancer is uncertain... - A cohort study of p27 localization in colon cancer, body mass index, and patient survivalShuji Ogino
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Brigham and Women s Hospital, Boston, and Harvard Medical School 02115, USA
Cancer Epidemiol Biomarkers Prev 18:1849-58. 2009..08). In conclusion, p27 alterations in colon cancer are associated with superior prognosis. Adverse prognostic effect of obesity seems limited to patients with nuclear p27 expression, suggesting a host-tumor interaction... - Systemic treatment of colorectal cancerBrian M Wolpin
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
Gastroenterology 134:1296-310. 2008.... - Adjuvant treatment of colorectal cancerBrian M Wolpin
Dana Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA
CA Cancer J Clin 57:168-85. 2007..Current randomized clinical trials in the adjuvant therapy of colorectal cancer are examining the value of adding agents known to be active in metastatic disease, including those that modify specific molecular targets... - CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinomaShuji Ogino
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
Virchows Arch 450:529-37. 2007..Additional studies are necessary to examine the role of DNA methylation in treatment efficacy... - Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancerBrian M Wolpin
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Clin Colorectal Cancer 6:208-13. 2006....